Friday turned out to be a nightmare for shareholders of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), after the drug maker announced that its ZoptEC Phase …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that it has entered into a new At Market Issuance Sales Agreement, dated April 27, 2017, with …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are rising almost 8% today on the heels of indicating it intends to file a new drug …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) investors are overwhelmingly excited today after the drug maker announced that following its meeting with thef FDA, on March …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced today that it has commenced a new “at-the-market” offering pursuant to its existing At Market Issuance (“ATM”) Sales …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) reported financial and operating results for the fourth quarter and year ended December 31, 2016.
Maxim analyst Jason Kolbert is optimistic on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) on the heels of the biotech firm indicating that the Pediatric …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that the Pediatric Committee (“PDCO”) of the European Medicines Agency (“EMA”) agreed to the Company’s Pediatric Investigation …
Maxim analyst Jason Kolbert weighed in on shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) with a $10.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that, following a comprehensive review of data obtained from the confirmatory Phase 3 clinical trial of Macrilen™ …
